MedPath

CS-1036 phase 2 study - dose response study of CS-1036 in patients with type 2 diabetes

Phase 2
Conditions
Patients with Type 2 Diabetes
Registration Number
JPRN-jRCT2080221036
Lead Sponsor
DAIICHISANKYO Co.,Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1. Patients diagnosed with type 2 diabetes mellitus
2. Outpatient

Exclusion Criteria

1. Patient with type 1 diabetes mellitus
2. Patient with clinically significant diabetic complications

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Postprandial glucose
Secondary Outcome Measures
NameTimeMethod
1. Fasting plasma glucose, insulin, glycoalbumin, and 1,5-anhydroglucitol<br>2. Safety and tolerability
© Copyright 2025. All Rights Reserved by MedPath